<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00194532</url>
  </required_header>
  <id_info>
    <org_study_id>27085-D</org_study_id>
    <nct_id>NCT00194532</nct_id>
  </id_info>
  <brief_title>Cefpodoxime vs Ciprofloxacin for Acute Cystitis</brief_title>
  <official_title>Cefpodoxime vs Ciprofloxacin for Acute Cystitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Urinary tract infection (UTI) is a very common problem in young healthy women, afflicting
      approximately one-half of women by their late 20s. One of the most common antibiotics used to
      treat UTIs is ciprofloxacin, usually for a total of three days. However, increasing
      resistance to this antibiotic has raised concerns about its overuse for cystitis and
      generated interest in alternative agents. An alternative antibiotic which is approved for use
      in UTIs is cefpodoxime. However, there are few studies evaluating the efficacy and tolerance
      of this compound when given in a 3-day regimen as is commonly used for treatment of UTI. The
      major purpose of this study is to assess the efficacy and tolerance of a 3-day regimen of
      cefpodoxime versus ciprofloxacin for treatment of acute uncomplicated cystitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Procedures subjects will undergo once they have read and signed the consent are:

      Questions about their medical and sexual history and current symptoms of UTI. They will be
      asked to provide a urine and peri-urethral sample and then are randomly assigned to one of
      the two treatment groups.They will be given a sheet to record symptoms at home. They will be
      asked to return to the clinic in 5-9 and 28-30 days after completing antibiotic
      therapy.Follow-up questions will be asked and urine and peri-urethral will be self collected
      at each visit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Cure</measure>
    <time_frame>28-30 days post therapy</time_frame>
    <description>Participants with clinical cure, i.e. free of urinary tract symptoms and requiring no further antibiotic treatment, to assess the efficacy of a 3-day regimen of cefpodoxime compared to ciprofloxacin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microbiologic Cure</measure>
    <time_frame>1-15 days post therapy</time_frame>
    <description>Elimination or decrease of causative uropathogen(s) in the mid-stream urine culture at follow-up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Urinary Tract Infection</condition>
  <arm_group>
    <arm_group_label>Cefpodoxime</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cefpodoxime 100mg twice a day(BID)for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ciprofloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ciprofloxacin 250mg twice a day (BID)for 3 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefpodoxime</intervention_name>
    <description>Cefpodoxime 100mg twice a day(BID)for 3 days</description>
    <arm_group_label>Cefpodoxime</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin</intervention_name>
    <description>Ciprofloxacin 250mg twice a day (BID)for 3 days</description>
    <arm_group_label>Ciprofloxacin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Nonpregnant females in good general health with symptoms of acute cystitis

        Exclusion Criteria:

          -  Pregnant,lactating, or not regularly contracepting: known anatomic abnormalities of
             the urinary tract; use of prophylactic antibiotics; history of allergy or intolerance
             to any of the study drugs; recent (&gt;2 weeks)exposure to an oral or parenteral
             antimicrobial; or history of UTI in the previous 1 month
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ann Stapleton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington, Department of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Hooton TM, Roberts PL, Stapleton AE. Cefpodoxime vs ciprofloxacin for short-course treatment of acute uncomplicated cystitis: a randomized trial. JAMA. 2012 Feb 8;307(6):583-9. doi: 10.1001/jama.2012.80.</citation>
    <PMID>22318279</PMID>
  </results_reference>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <results_first_submitted>March 30, 2011</results_first_submitted>
  <results_first_submitted_qc>March 30, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 28, 2011</results_first_posted>
  <last_update_submitted>June 3, 2014</last_update_submitted>
  <last_update_submitted_qc>June 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Ann Stapleton</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>UTI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Cystitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Cefpodoxime</mesh_term>
    <mesh_term>Cefpodoxime proxetil</mesh_term>
    <mesh_term>Ceftizoxime</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ciprofloxacin</title>
          <description>Ciprofloxacin 250 mg BID X 3 days</description>
        </group>
        <group group_id="P2">
          <title>Cefpodoxime</title>
          <description>Cefpodoxime 100 mg BID X 3 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="150"/>
                <participants group_id="P2" count="150"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="150"/>
                <participants group_id="P2" count="150"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ciprofloxacin</title>
          <description>Ciprofloxacin 250 mg BID X 3 days</description>
        </group>
        <group group_id="B2">
          <title>Cefpodoxime</title>
          <description>Cefpodoxime 100 mg BID X 3 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="150"/>
            <count group_id="B2" value="150"/>
            <count group_id="B3" value="300"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24" lower_limit="18" upper_limit="55"/>
                    <measurement group_id="B2" value="23" lower_limit="17" upper_limit="44"/>
                    <measurement group_id="B3" value="24" lower_limit="17" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                    <measurement group_id="B2" value="150"/>
                    <measurement group_id="B3" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                    <measurement group_id="B2" value="150"/>
                    <measurement group_id="B3" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Cure</title>
        <description>Participants with clinical cure, i.e. free of urinary tract symptoms and requiring no further antibiotic treatment, to assess the efficacy of a 3-day regimen of cefpodoxime compared to ciprofloxacin</description>
        <time_frame>28-30 days post therapy</time_frame>
        <population>modified ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Ciprofloxacin</title>
            <description>Ciprofloxacin 250 mg BID X 3 days</description>
          </group>
          <group group_id="O2">
            <title>Cefpodoxime</title>
            <description>Cefpodoxime 100 mg BID X 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cure</title>
          <description>Participants with clinical cure, i.e. free of urinary tract symptoms and requiring no further antibiotic treatment, to assess the efficacy of a 3-day regimen of cefpodoxime compared to ciprofloxacin</description>
          <population>modified ITT</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140"/>
                    <measurement group_id="O2" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not cure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microbiologic Cure</title>
        <description>Elimination or decrease of causative uropathogen(s) in the mid-stream urine culture at follow-up</description>
        <time_frame>1-15 days post therapy</time_frame>
        <population>Per protocol. Participants were eligible for analysis if they had an enrollment urine containing uropathogens and a urine specimen taken at follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciprofloxacin</title>
            <description>Ciprofloxacin 250 mg BID X 3 days</description>
          </group>
          <group group_id="O2">
            <title>Cefpodoxime</title>
            <description>Cefpodoxime 100 mg BID X 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Microbiologic Cure</title>
          <description>Elimination or decrease of causative uropathogen(s) in the mid-stream urine culture at follow-up</description>
          <population>Per protocol. Participants were eligible for analysis if they had an enrollment urine containing uropathogens and a urine specimen taken at follow-up.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123"/>
                    <measurement group_id="O2" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not cure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ciprofloxacin</title>
          <description>Ciprofloxacin 250 mg BID X 3 days</description>
        </group>
        <group group_id="E2">
          <title>Cefpodoxime</title>
          <description>Cefpodoxime 100 mg BID X 3 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastrointestinal(GI) side effects</sub_title>
                <description>nausea, vomiting, loose stools, abdominal discomfort, other GI</description>
                <counts group_id="E1" events="30" subjects_affected="23" subjects_at_risk="137"/>
                <counts group_id="E2" events="26" subjects_affected="21" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <description>included under GI side effects</description>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="137"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>loose stools</sub_title>
                <description>included under GI side effects</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="137"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>abdominal discomfort</sub_title>
                <description>included under GI side effects</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="137"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>central nervous system (CNS) side effect</sub_title>
                <description>headache, dizziness</description>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="137"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <description>included under CNS side effects</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="137"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>vaginal side effects</sub_title>
                <description>vaginal discomfort, discharge, itching, or self-diagnosed yeast</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="137"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ann Stapleton, MD</name_or_title>
      <organization>University Of Washington</organization>
      <phone>206-616-4121</phone>
      <email>stapl@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

